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ent-Kaurene (1) was ﬁrstly isolated from the leaf essential oil of
the New Zealand kauri (Agathis australis Salisb),1 a plant locallycalled kauri pine. This type of diterpenoids with negative optical
rotation was named as ent-kauranoids, which means opposite to
the stereochemistry of kauranoids. ent-Kauranoids are a large fam-
ily of diterpenoids with dazzling structural features and a broad
range of bioactivities that have intrigued numerous endeavors
from the biosynthesis and chemical synthesis perspectives in the
past half century. In this viewpoint, we highlight key elements to
24 L. Zhu et al. / Tetrahedron Letters 56 (2015) 23–31construct the bridged ring system rather than to record all syn-
thetic effects in detail. Based on structural features of ring system,
ent-kauranoids bearing bicyclo[3.2.1]octane can be categorized
into three sub-classes: (Class I) retaining the original complete
6/6/6/5 ring system (A–B–C–D), such as ent-kaurene (1), steviol
(2),2 cafestol (3),3 atractyligenin (4),4 neotripterifordin (5),5
oridonin A (6),6 shikoccidin (7),7 and longikaurin E (8)8 (Fig. 1);
(Class II) containing an oxidatively cleaved or rearranged modiﬁed
B-ring, such as gibberellin A12 (9),9 sculponeatin N (10),10 and
maoecrystal V (11)11 (Fig. 2); (Class III) degradation of A ring as
in nor-ent-kauranoids, such as platensimycin (12)12 (Scheme 2).
The structural feature of bicyclo[3.2.1]octane has been a synthetic
hot topic in past decades, two comprehensive reviews have
appeared to summarize numerous approaches to furnish this key
skeleton.13a,b A very recent review contributed by Thomson and
co-workers emphasized the synthetic efforts on Isodon diterpenes
including some most intriguing B-ring oxidized structures (Class
II), such as sculponeatin (10) and maoecrystal V (11).13c Synthesis
of the A-ring degraded ent-kauranoids such as platensimycin (12)
has been discussed in great detail in several excellent reviews.14
We here thus concentrate on the development of novel strategies
and tactics toward total synthesis of ent-kauranoids bearing a
6–6-fused bicyclo[3.2.1]octane as shown in Figure 1.ent-kaurene (1)
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Figure 1. Representative ent-kauranoids with normal ring system (Class I).
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Figure 2. Other ent-kauranoids with oxidized or rearranged A/B (Class II and III).(±)-Kaurene (Ireland)
The ﬁrst chemical total synthesis of any member of kauranoids
was inaugurated by Ireland and co-workers in 1962.15 The
accomplishment of (±)-kaurene (1) was elegantly implemented
the Claisen rearrangement (Marbet–Saucy enol–ether process) to
introduce the quaternary carbon center at C(8) (Scheme 1). The
synthesis commenced with a well-designed aldol/Michael/aldol
process from m-methoxybenzaldehyde (13) to furnish a multi-
substituted cyclohexenone 14. Hydrogenation of the conjugated
diene and ketone reduction was amenable for the subsequent
Friedel–Crafts cyclization to deliver a tricyclic motif 15. After ﬁve
straightforward steps involving the key Birch reduction and
Claisen rearrangement, a corresponding acetal 17 was obtained
and further subjected to hydroboration and oxidation, the minor
regioisomer 18 then underwent deprotection and aldol reaction
to establish the bicyclo[3.2.1]octane framework. (±)-Kaurene (1)
was completed after regioselective oleﬁnation and Wolff–Kishner
deoxygenation at C(14). It is the ﬁrst time to apply aldol reaction
to construct the bicyclo[3.2.1]octane bridged ring and an excep-
tional isolated yield (96%) was achieved.
(±)-Kaurenoic acid and (±)-kaurenol (Mori)
()-Kaurenoic acid (1a) (also known as kaur-16-en-19-oic acid)
is one of tetracyclic diterpenes isolated from Ricinocarpus stylosus
Diels, found having gibberellin-like activity as well as ()-kaurenol
(1b) (kaur-16-en-19-ol).16 In 1966, Mori et al. reported total syn-
theses of both (±)-kaurenoic acid (1a) and (±)-kaurenol (1b)
(Scheme 2).17 Aldol condensation of ketone 20 with methyl acroy-
lacetate under the basic conditions afforded a tricyclic keto ester
21, which was readily converted to 22 through methylation at
C(4) and deoxygenation via a Raney-Ni reduction of ethanedithiol.
After demethylation with HI in acetic acid and re-esteriﬁcation
with diazomethane, the aromatic ring was completely hydroge-
nated with Rh–Pt bimetallic catalyst. Jones oxidation revealed
the ketone group at C(14) in 23. Prior to introducing a substituent
at C(8), the more accessible C(13) was ﬁrstly masked by a n-buty-
lthiomethylene protecting group. The quaternary carbon center at
C(8) was furnished with a facile allylation. After removal of theH O
OO
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OMe
CO2Me
H
O
CO2Et
10 steps
CO2Me
H
O
O
(±)−steviol (2)
6 steps
24%
1) BH3•THF
2) CrO3
acetone
48% (2 steps)
1) Ph3P=CHCH3
2) BH3•THF
3) CrO3-acetone
4) NaOMe
53%
(4 steps)
66%
3M HCl
1) Ac2O
2) NH2OH•HCl
75%
(3 steps)
5 steps
9%
30 31
32 33
34 35
H
5%
OHCO2Me
COMe
OAcCO2Me
NHCOMe
CO2H
OH
CO2Me
O
O
CO2Me
O
O
O
O
36
OAcCO2Me
OAc
AcOH-Ac2O
NaNO2
3) MsCl
40%
29
1313
13
16
Scheme 3. Mori’s total synthesis of (±)-steviol (2).
32
(±)− steviol (2)
3M HCl
93%
37
chromic
acid
95%
Zn-Hg
41%
42%
2) KO tBu
38
39
(2 steps)
1) Ph3P=CH2
CO2Me
O
O
O
CO2Me
O
OH
CO2Me
O
O
OCO2Me
OH
CO2H
OH
CO2Me
OH
OH
13
16
13
16
13
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L. Zhu et al. / Tetrahedron Letters 56 (2015) 23–31 25protective group at C(13), the allylic group was scissored with
osmium tetroxide–sodium periodate and the resultant aldehyde
underwent aldol reaction to build a bicyclo[3.2.1]octane as illus-
trated in Ireland’s synthesis.15 The corresponding hydroxy ketone
25 was then protected by DHP (dihydropyran) and the ketone
group at C(14) was reduced by a Wolff–Kishner protocol. With
the treatment of acid, the resulting acid 26was then exposed upon
Jones oxidation and esteriﬁcation to provide a ketone ester 27,
which was subjected to reduction and Wittig oleﬁnation to give
(±)-kaurenol (1b). Since ()-kaurenol (1b) had been converted to
()-kaurenoic acid (1a),16a this synthesis constitutes a general
route to access both the acid and alcohol.
(±)-Steviol (Mori)
Steviosides were isolated from leaves and stems of Stevia rebau-
diana.3 Stevia, derived from steviol glycosides, has been approved
as a non-nutritive sweetener for human consumption by the Euro-
pean Food Safety Authority in 2011. Hydrolysis of stevioside affor-
ded steviol (2), which was documented having gibberellin-like
activity.18 Mori and co-workers reported the ﬁrst total synthesis
of (±)-steviol (2).19 The key tricyclic intermediate 30 was built
upon 2-carboxylate cyclohexanone as a starting material through
a lengthy process (Scheme 3). Implementation of the Ireland’s tac-
tic including Birch reduction and Claisen rearrangement resulted in
an acetal 31 in 24% overall yield with a 6-step sequence. Selective
hydroboration–oxidation sequence at C(13) provided ketone 32,
which was also indicated as the major regioisomer in the Ireland
synthesis of kaurane (1) (Scheme 1).15a The following Wittig reac-
tion and the second hydroboration–oxidation sequence delivered
ketone 33. The intramolecular aldol reaction proceeded smoothly
to form the bicyclo[3.2.1]octane skeleton in 34. Further functional-
ization was able to introduce an amidyl group at the bridged car-
bon C(13). The following 5 steps ﬁnally completed the total
synthesis of (±)-steviol (2). The second generation of synthetic
route dramatically improves the synthesis efﬁciency due to thediscovery of novel fragmentation of cyclopropane. With the treat-
ment of the advanced intermediate 32with HCl, aldol reaction pro-
vided a bicyclo[2.2.2]octane atisane skeleton as in 37 (Scheme 4).
After oxidation of hydroxyl group with chromic acid, diketone 38
was treated with zinc amalgam in hydrochloric acid to undergo
an intramolecular pinacol condensation. The cyclopropane bearing
vicinal diols was further fragmented to give a-hydroxyl ketone 39,
a product was suggested to be kinetically favored, which was
guided to the total synthesis of (±)-steviol (2). In this route the
Clemmensen reduction of diketone 38 beautifully altered bicy-
clo[2.2.2]octane to bicyclo[3.2.1]octane in a single step. This con-
cise strategy was later adopted in Baran’s synthesis of steviol (2).
(±)-Steviol methyl ester (Ziegler)
In 1977, Ziegler and Kloek completed total synthesis of (±)-stev-
iol methyl ester (47) (Scheme 5).20 The Hagemann’s ester (40)21
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26 L. Zhu et al. / Tetrahedron Letters 56 (2015) 23–31was ﬁrstly converted to enone 41, which was further brought to a
tricyclic acid 42. Three continuous stereogenic centers on the A-
ring of ent-kaurane skeleton were correctly installed. After the
classic Birch reduction and hydrolysis, the resulting enone was fur-
ther masked as thioketal which was readily performed desulfuriza-
tion to give oleﬁnic methyl ester 43. The following ozonolysis in
methanol and aldol condensation provided the requisite aldehyde
45. The innovative photo-addition of allene with enone proceeded
in a good facial selectivity when the substance was exposed upon
irradiation. The resulting aldehyde was further converted to a mes-
ylate intermediate 46. In aqueous acetone, a plausible concerted
[1,2]-migration resulted in a ring expansion and solvolysis to form
steviol methyl ester (47). Although the whole solvolytic ring
expansion was leading to bicycle[3.2.1]octane in only 3% yield,
the pioneering photo-addition and novel rearrangement inspire
succeeding method developments.O
EtO2C
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Scheme 7. Snider’s total synthesis of (±)-isosteviol (56).(±)-Steviol and (±)-isosteviol (Baran)
In 2013, Baran and co-workers nicely implemented allene
photo-addition and cyclopropane fragmentation to complete the
total synthesis of (±)-steviol (2) (Scheme 6).22 To establish the cor-
rect stereochemistry in the regioselective arene-terminated cat-
ionic cyclization toward a tricyclic system 50, epoxide 49 was
chosen as the precursor, which was easily prepared from the clas-
sic form as 48. Iron trichloride-initiated polyene cyclization efﬁ-
ciently delivered 50. The hydroxyl group at C(3) was then
eliminated via the Mitsunobu reaction conditions. The following
hydrogenation and Birch reduction generated enone 51 in excel-
lent yield. Allene [2+2] photo-cycloaddition provided cyclobutane
52, whose stereochemistry outcome was in contrast to Ziegler’s
synthesis.20 The subsequent one-pot process involving ozonolysis
and retro-Claisen/Claisen condensation was successfully delivered
a thermodynamically favorable bicyclo[2.2.2]octane diketone 53.
The modiﬁcation of Mori’s protocol19a,c eventually led to the cyclo-
propane triacetate 54 and the following reductive rearrangement
afforded 55 in excellent yield and regioselectivity. Surprisingly,
ketol 55 was inert to the standard Wittig oleﬁnation, a Rhodium-
catalyzed oleﬁnation was thus realized with trimethylsilyldia-
zomethane. Two steps of oxidation furnished the synthesis of
(±)-steviol (2). Isosteviol (56) was initially synthesized from(±)-steviol (2) with acid-induced rearrangement. These authors
again presented here a high-yielding HBr-promoted pinacol-type
rearrangement to convert (±)-steviol (2) into (±)-isosteviol (56), a
beyerane skeleton biogenetically proposed through a similar rear-
rangement from ent-kaurane.
(±)-Isosteviol (Snider)
In 1998, Snider and co-workers disclosed a masterpiece of man-
ganese acetate-initiated oxidative radical carbocyclization to com-
plete the synthesis of (±)-isosteviol (56) (Scheme 7).23 Relying on
impressive achievements contributed from this group,23b they
envisioned b-keto ester 57would be an ideal precursor. With treat-
ment of Mn(OAc)3 and Cu(OAc)2, oxidative free-radical cyclization
L. Zhu et al. / Tetrahedron Letters 56 (2015) 23–31 27afforded a tetracyclic skeleton ester 58 in a highly regioselective
and stereoselective manner, establishing six continuous chiral car-
bon centers including four quaternary stereocenters in a single
operation. The full beyerane skeleton required further six transfor-
mations to provide (±)-isosteviol (56) in 51% overall yield. It poses
a challenge for future development on the stereochemical control
in the radical cyclization to access the kaurene-type structure.
(±)-Cafestol and atractyligenin (Corey)
Cafestol (3) is an ent-kaurane in coffee, especially with high
quantity in unﬁltered coffee drinks such as Arabica coffee or Turk-
ish coffee.4 It has shown interesting biological activities, such as
anti-inﬂammation, cholesterol elevation, neuroprotective effect,
and was recently found to potentially resist human malignant
pleural mesothelioma (HMPM).24 Atractyligenin (4), also occurred
in Arabica coffee, was known for its deadly toxicity since it was
able to block the transport of adenosine diphosphate into
mitochondria to decrease ATP production.5 In 1987, Corey and
co-workers reported total synthesis of both (±)-cafestol (3) and
(±)-atractyligenin (4) using a similar strategy, which can be viewed
as a cyclopropanation methyl cation-initiated cationic cyclization
(Scheme 8A).25 Copper-catalyzed cyclopropanation derived keto-
ester 61 was designed to synthesize corresponding precursors. In
the presence of excess triﬂic anhydride, the primary alcohol was
activated to trigger the subsequent ring-opening of cyclopropaneCO2Me
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Scheme 8. Corey’s total syntheses of (±)-cafestol (3) and (±)-atractyligenin (4).to form allylic cation, which then proceeded to construct the B-
ring. The ent-kaurane framework was established in a single step.
After several transformations, the synthesis of (±)-cafestol was
completed. The novel cationic cyclization was further applied to
the synthesis of (±)-atractyligenin (4) (Scheme 8B). In 1997, an
enantioselective synthesis of the ester 64 (94% ee) using CBS-
reduction as a key step was developed and it ensures an enantiose-
lective synthetic route to access atractyligenin (4).26 The elegance
of cationic cyclization leading to 62/66 forges a conceptually novel
approach for the synthesis of ent-kaurane bicyclo[3.2.1]octane
skeleton. Cyclopropyl methyl alcohol is a profound cationic cycli-
zation precursor that would ﬁnd its applications in modern organic
synthesis.
()-Neotripterifordin (Corey)
Neotripterifordin (5) was isolated from the Chinese medicinal
plant Tripterygium wilfordii and identiﬁed as a potent inhibitor of
HIV replication (EC50 = 25 nM).6 In 1997, Corey and Liu completed
the enantioselective synthesis of neotripterifordin (5) and reas-
signed its stereochemistry at C(16).27 A readily accessible allylic
alcohol 67 was transformed to chiral epoxide 68 in 96% ee through
Sharpless asymmetric epoxidation (SAE) (Scheme 9). Followed by
titanium tetrachloride-induced cyclization, three stereogenic car-
bon centers and tricyclic system were nicely set up. A possible
bidentate coordination of the benzyloxy and oxirane oxygens with
titanium tetrachloride might be responsible for the highly stereo-
chemical control where a cationic character may not be feasible.
The hidden aldehyde at C(20) was revealed to form an acetal
functional group until Birch reduction of the aromatic ring and
isomerization were completed. Allene photo-cycloaddition with
a,b-unsaturated ketone 70 afforded a major a-adduct 71 in 72%
yield. After ozonolysis of the terminal alkene in 71, methanolysis
and selective DIBAL-H reduction yielded a hydroxyl aldehyde 72.
The secondary alcohol was then converted to xanthate 73 in which
an alkyne moiety was derived from aldehyde with Ohira–Best-
mann reagent. nBu3SnH–AIBN effected 5-exo-dig radical cyclization
completed the bicyclo[3.2.1]octane skeleton which eventually was
converted to the ﬁnal target, neotripterifordin (5). This syntheticOMe
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Scheme 9. Corey’s total synthesis of ()-neotripterifordin (5).
28 L. Zhu et al. / Tetrahedron Letters 56 (2015) 23–31work not only provided excellent yields of many steps, but also
afforded outstanding enantio- and stereo-control of annulation as
well as the effective method toward bicyclo[3.2.1]octane with a
free radical-based cyclization. It is noteworthy that titanium tetra-
chloride-promoted cyclization of chiral epoxide with conjugated
diene furnished three continuous stereogenic carbon centers,
delivering the A-B ring of ent-kaurane in one step.
(±)-Cafestol (Hong)
The synthetic plan toward cafestol should be taken with pains-
taking attention due to the sensitivity of furan as implied in Corey’s
landmark synthesis.25a To overcome this fragile functionality, with
the inspiration of late-stage formation of furan in the biogenetic
proposal of cafestol, Hong and co-workers realized the total syn-
thesis of (±)-cafestol (3) with a different approach featuring a
SmI2-promoted cyclization to furnish the key bicycle[3.2.1]octane
moiety (Scheme 10).28 Starting with Suzuki coupling between
two readily available components, the resultant was oxidized and
the corresponding aldehyde 77 was underwent Et2AlCl-promoted
aldehyde-ene/Friedel–Crafts cyclization to yield the requisite
tricyclic system 78 in high stereoselectivity and regioselectivity.
The following critical Birch reduction and Eschenmoser–Claisen
rearrangement allowed to install the quaternary carbon center at
C(8). In order to carry out the programmed radical coupling
between C(16) and C(13), a double bond shift was ﬁrstly realized
through an iodine-mediated esteriﬁcation. Lactol 80, derived from
DIBAL-H reduction of lactone, was effectively transformed to a
bridge structure with samarium(II) iodide-promoted lactol–alkene
coupling. After deoxygenation at C(14) via Barton–McCombie rad-
ical process, the furan formation was achieved through a three-
step sequence enabled by Au-catalyzed cyclization. This protocol
of introducing the sensitive furan moiety in complex targets proves
to be efﬁcient. The stereoselective installation of b-OH group at
C(14) also offered an advanced intermediate to access other
oxygenated ent-kauranoids with signiﬁcant bioactivities, like
oridonin A (6).
()-Oridonin A (Zhou)
ent-Kauranoids are the major constituents of Rabdosia (=Isodon)
plant species, and so far >1300 highly oxygenated ent-kauranoidsOH
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Scheme 10. Hong’s total synthesis of (±)-cafestol (3).have been isolated from this genus, including oridonin A (6).7 With
its potent anticancer, antibacterial, and anti-inﬂammatory bioac-
tivities,29 its dazzling oxygenated architecture attracted total syn-
thesis and derivatization. In 1992, Zhou and co-workers pioneered
a relay synthesis of ()-oridonin A (6) from ()-kamebakaurin
(83), another ent-kauranoid isolated from Rabdosia excsia.30 In their
synthesis (Scheme 11), the C(14)-hydroxyl group was ﬁrst pro-
tected as an acetate, while the C(1) and C(20) hydroxyl groups
were masked with acetonide in compound 84. Oxidation of
C(7)-OH with PDC followed by enolization with trimethylsilyl
triﬂate afforded vinyl silyl ether 85. Facial selective epoxidation
of C(6)–C(7) double bond with mCPBA and subsequent ring-
opening by the C(20) hydroxyl group under acidic conditions
provided hemiketal 87. A mild hydrolysis with oxalic acid
completed the synthesis of ()-oridonin A (6). The synthesis only
took 7 steps in 9% overall yield, providing a new synthesis perspec-
tive for this promising anticancer lead and forges future modiﬁca-
tion of oridonin analogous for biological evaluation.
Dimethylshikoccidin (Paquette)
Besides oridonin A (6), plants of genus Rabdosia are also well
known to produce structurally unusual tetracyclic diterpenoids,
including the antitumor agent shikoccidin (7 in Fig. 1), whose C(9)
is exceptionally hydroxylated.8 In 1997, Paquette and co-workers
developed an innovative transannular Michael-aldol approach to
furnish the total synthesis of dimethylshikoccidin (95)
(Scheme 12).31 An enantiomeric enrichedWieland–Mischer ketone
88 (>99% ee)32 was functionalized to give diketone 89, which was
further condensed with aldehyde 90 to provide a spiro diketone
91 as 1:1 mixture of epimers for the protected C(15)-hydroxyl
group. The mixture was subjected to regioselective reduction of
diketone by DIBAL-H. The resulting equatorial C(7)-hydroxyl group
(a conﬁguration) was converted to methyl ether and the corre-
sponding mono-ketone was reacted with vinylmagnisum bromide
to exclusively deliver 92. The following key oxy-Cope rearrange-
ment resulted in a [7.2.1] cyclic system 93with proper stereochem-
istries. After installation of methylene on the cyclopetanone ring,
heated with oxalic acid at 65 C for 3 h, dienone 94was isomerized
to dimethylshikoccidin (95), where the center bond between the B
and C rings was elegantly constructed through a transannular
cascade cyclization. Hydrolysis of the methyl ether at C(7) andOH
H
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Scheme 11. Zhou’s synthesis of ()-oridonin A (6).
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Scheme 12. Paquette’s synthesis of dimethylshikoccidin (95).
L. Zhu et al. / Tetrahedron Letters 56 (2015) 23–31 29C(14) toward shikoccidin (7) remains unexplored. Nevertheless, it is
a uniquely different synthetic entry of connecting C(8) and C(9) as
the ﬁnal key step for ent-kauranoids.
()-Methyl kaurenoate (Ihara)
Ihara and Toyota reported the synthesis of (–)-methyl kaureno-
ate in 2000 (Scheme 13).33c The synthesis started with asymmetric
Michael addition of cyclohexanone 96 to generate chiral quater-
nary center adjacent to the carbonyl group. It is impressive that
Pd-catalyzed oxidative cycloalkenylation reaction of cross-conju-
gated silyl enol ether derived from enone 98 delivered bicy-
clo[3.2.1]octane 99 in good yield. A subsequent copper-catalyzed
Michael addition of enone in 99 proceeded with an excellent facial
selectivity. After a chain elongation with double Wittig oleﬁnation,O O
CO2Me68%
O
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3 steps
50%
O
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Scheme 13. Ihara’s total synthesis of ()-methyl kaurenoate (103).an intramolecular inverse electron demand Diels–Alder (IEDDA)
reaction afforded a pentacyclic cycloadduct 102 (dr 85:15), which
constitutes the A and B rings of ent-kaurene. A late-stage carboeth-
oxylation of vinylbromide, removal of protecting group, and
Wolff–Kishner reduction produced ()-methyl kaurenoate (103).
The beauty of palladium-catalyzed cycloalkenylation developed
in Ihara and Toyota’s seminal work was adopted to furnish the
bicyclo[3.2.1]octane skeleton in platensimycin synthesis14 and
the latest Reisman’s synthesis of longikaurin E34 (vide infra). The
intramolecular Diels–Alder reaction is also noteworthy to rapidly
construct the A/B ring system with good stereoselectivity. Clearly
this inspiring research represents a textbook example for terpe-
noids synthesis.
()-Longikaurin E (Reisman)
Reisman and co-workers reported the synthesis of ()-longikau-
rin E (8), a B-ring oxidized ent-kauranoid, with an unprecedented
SmI2-mediated reductive intramolecular coupling of aldehyde and
ester to furnish the B-ring with the correct stereochemistry at
C(6) and C(7).34 The synthesis was begun from the known
()-cyclogeraniol (104), which was readily converted to epoxide
105 in a diastereomeric ratio of 3:1. The subsequent TiIII-promoted
radical epoxide–alkene coupling was optimized to deliver spirolac-
tone 106 as a single stereoisomer in 76% yield (Scheme 14). After
alkylation with alkyl iodide 107 and formation of enone with
selenium chemistry, selective desilylation and oxidation converted
108 to aldehyde 109. In presence of SmI2, a stereoselective radical
coupling nicely set a hydroxyl group at C(11) and a tertiary carbon
center at C(9) in compound 110. With the following protection and
activation of C(8) via a silyl enol ether, an intramolecular Heck-type
cyclization with Pd(OAc)2–O2 gave bicyclo[3.2.1]octane 112. Global
deprotection of MOM at C(11)–OH and TBS at C(6)–OH, the subse-
quent oxidation converted the primary alcohol into aldehyde and
the secondary alcohol at C(11) was further masked as an acetate
form in 113. Reisman and co-workers again applied the powerfulOH
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Scheme 14. Reisman’s total synthesis of ()-longikaurin E (8).
30 L. Zhu et al. / Tetrahedron Letters 56 (2015) 23–31SmI2-mediated radical coupling to connect C(6) and C(7) to furnish
the hydroxyl-hemiketal motif in ()-longikaurin E (8). The three-
steps-in-row from 113 to 8was exceptional in terms of the densely
functionalized skeleton in such high oxidation state and rigid tar-
get. And it is evenmore profound that this strategywas successfully
applied to other ent-kauranoids and ultimately leading to a uniﬁed
approach reported by this group.35
Biogenesis insight and outlook
Nature has evolved sophisticated yet visually simple chemical
reactions to orchestrate complex molecules. For the critical bicy-
clo[3.2.1]octane architecture in ent-kauranoids, biogenesis of ent-
kaurane is generally believed upon the cationic cyclization of
()-copalyl diphosphate (CPP) by a single enzyme kaurene syn-
thase (Scheme 15).36 This classic mechanism proceeds via ioniza-
tion of the allylic diphosphate ester bond in ()-CPP to trigger
initial cyclization to ent-pimarenyl cation, followed by secondary
cyclization to the depicted ent-beyeranyl cation. The subsequent
1,2-alkyl shift (Wagner–Meerwein rearrangement) may go
through an ent-trachylobanyl cation (a nonclassic cation)37 en route
to the ent-kauranyl cation that is quenched by deprotonation to
yield ent-kaurene (1).
The above proposal remains in debate since the tertiary to sec-
ondary carbocation transition is energetically unfavorable.
Recently, based on comprehensive computational analysis,38 Tan-
tillo and co-workers suggested that previously proposed secondary
carbocation intermediates are avoided if a triple shift rearrange-
ment (up to three alkyl or hydride shifting events) is coupled into
concerted processes which are predicted to occur insteadOPP
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Scheme 16. Modiﬁed biogenesis of ent-kauranoids.
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Scheme 15. Biogenesis of ent-kauranoids.(Scheme 16). Peters and co-workers also pointed out that an ion-
pairing (see insert) would be critical for the possible ent-beyeranyl
cation intermediate.39 In regard of the difﬁculty in Oikiwa’s initial
biomimetic endeavor,40 this updated proposal may shape future
experimental design on these novel rearrangements and ultimately
realize the biomimicry in ent-kaurene synthesis.
This Digest highlighted the total synthesis of selected ent-
kauranoids and innovative strategies to constitute the bicy-
clo[3.2.1]octane skeleton. Many of these methods remain effective
in this ﬁeld and continue as fruitful resources to inspire total syn-
thesis and method development in this day. It is interesting that
some approaches mimicked the biogenesis pathway at some
extent. The striking case is Snider’s synthesis utilizing radical cycli-
zation to build the beyerane framework. Corey’s cationic cycliza-
tion was ingeniously initiated in a reverse order as comparison
to the biosynthesis of diterpenoids. Mori and Baran’s work created
the structurally unique cyclopropane intermediate which is resem-
blance of some biosynthesis intermediates and natural product
framework. Mechanistic investigation on the biogenesis of ent-
kaurene and the biomimicry study from the synthesis prospect
are continuing to be the central theme to understand the origin
of this vast category of natural products.Acknowledgments
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